Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements GlobeNewswire Inc. · 2025-06-25 PRTG
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 GlobeNewswire Inc. · 2025-04-28 PRTG
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial GlobeNewswire Inc. · 2025-03-12 PRTG
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company GlobeNewswire Inc. · 2025-01-06 PRTG